TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences Co., Ltd. announced that its anti-IL-17A monoclonal antibody, JS005, has successfully met the primary and secondary endpoints in a Phase III clinical study for treating moderate to severe plaque psoriasis. This achievement marks a significant advancement in the company’s product pipeline, potentially enhancing its market position in the autoimmune disease treatment sector. The study demonstrated that JS005 significantly improved psoriasis symptoms compared to a placebo, with good safety results, and the company plans to submit a new drug application soon.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative therapies for autoimmune diseases and other conditions. The company specializes in monoclonal antibodies, with a market focus on diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis.
Average Trading Volume: 13,794,433
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.13B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.